Methylphenidate Stada (Methylphenidate Hydrochloride)

Methylphenidate blocks the reuptake of dopamine and norepinephrine in the brain, increasing their levels at synaptic junctions. The elevated neurotransmitter activity enhances attention, focus, and alertness, which underpins its therapeutic benefit in ADHD and narcolepsy.

The dose of Methylphenidate Stada is individualized by the prescribing clinician based on the patient’s age, diagnosis, response, and tolerability. Healthcare providers determine the appropriate starting dose and any subsequent adjustments, following local prescribing guidelines.

Safety data for methylphenidate in pregnancy and lactation are limited. Clinicians must weigh potential benefits against possible risks to the fetus or infant. If treatment is deemed necessary, it should be used only under close medical supervision.

To order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Methylphenidate Stada belongs to the central nervous system stimulant class, similar to amphetamine‑based products. Compared with amphetamines, methylphenidate primarily blocks dopamine reuptake, whereas amphetamines also increase dopamine release. Both improve ADHD symptoms, but individual response and side‑effect profiles may differ.

Store the product at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, excessive heat, and direct sunlight. Keep the medication out of reach of children and do not use if the packaging is damaged.

Methylphenidate Stada is taken orally. The tablet (or capsule) should be swallowed whole with a glass of water, preferably in the morning and, if prescribed, a second dose early in the afternoon to avoid insomnia. Follow the prescriber’s instructions regarding timing and food.

Serious risks include cardiovascular events such as hypertension or tachycardia, emergence of psychotic symptoms like hallucinations, and severe allergic reactions that may present as rash, swelling, or anaphylaxis. Patients should seek immediate medical attention if any of these occur.

Methylphenidate Stada is contraindicated in individuals with known hypersensitivity to methylphenidate or any excipients, those who have taken monoamine oxidase inhibitors within the past 14 days, and patients with severe cardiovascular disorders, uncontrolled hypertension, or certain psychiatric conditions without proper supervision.